Abstract In this paper, for time-to-event data, we propose a new statistical framework for casual inference in evaluating clinical utility of predictive biomarkers and in selecting an optimal treatment for a particular patient. This new casual framework is based on a new concept, called Biomarker Adjusted Treatment Effect (BATE) curve. The BATE curve can be used for assessing clinical utility of a predictive biomarker, for designing a subsequent confirmation trial, and for guiding clinical practice. We then propose semi-parametric methods for estimating the BATE curves of biomarkers and establish asymptotic results of the proposed estimators for the BATE curves. We also conduct extensive simulation studies to evaluate finite-sample properties of the proposed estimation methods. Finally, we illustrate the application of the proposed method in a real-world data set.
Introduction
Due to complexity of cancer, current staging and risk-stratification methods in oncology, while helpful, often fail to adequately predict malignancy aggressiveness and/or response to a specific treatment. The rapid advance of molecular genetic technology and accompanying proliferation of molecular diagnostics companies have set the stage for a new era in personalized medicine. This development allows the tumornode-metastasis (TNM) staging system to incorporate additional biomarkers, such as gene expression data, which may provide more precise information for risk stratification and treatment selection. By identifying patients who are at high risk and who are more likely to benefit from a given treatment, we hope to be able to provide the most effective treatment to those who are most in need.
A predictive marker is a biomarker that predicts the differential efficacy (benefit) of a particular therapy based on the value of a biomarker (e.g., only patients expressing the biomarker will respond to the specific treatment or will respond to a greater degree than those without the biomarker) (see [16] ). To apply these exciting results to maximize patient benefit, we need to develop a systematic statistical Zhou X H et al. Sci China Math August 2012 Vol. 55 No. 8 methodology to assess the clinical utility of promising biomarkers for predicting patients' responses to particular treatments.
Most of the current statistical methods for assessing the clinical utility of a predictive biomarker are based on a comparison of estimated survival curves between a treatment and control group, stratified by the biomarker values. One main limitation of these subgroup approaches is that, if the biomarker yields a continuous-scale, such the approach requires dichotomization, which is artificial and may lose important information. Second, such the approach does not adequately quantify the clinical utility of predictive biomarkers. Specifically, many biomarkers that may have a significant p-value for interaction test, but do not have true clinical utility. Statistical significance does not imply clinical relevance.
Subpopulation treatment effect pattern plot (STEPP) (see [2, 3] ) is another subgroup method. Since this method fits a Cox model to each subgroup separately, this method requires that the size of each subgroup is large enough to estimate the treatment effects and fit Cox models reliably. For non-survival data, Cai et al. [5] extended the idea of STEPP to examine the treatment difference at a subject-level with multiple covariates and proposed a systematic, 2-stage method to select those patients who would benefit from the new treatment. They also derived valid pointwise and simultaneous inferences about the true average treatment difference for each group of patients, defined by an estimated parametric index score.
Two additional methods for assessing clinical utility of predictive biomarkers have been also proposed in the literature (see [9, 12] ). Freidlin and Simon [9] proposed a design that combines prospective development of a gene expression-based classifier to select sensitive patients with a properly powered test for overall effect, by assuming the biomarker is binary. Jiang et al.
[12] extended Freidlin's design to allow a continuous-scale biomarker and proposed a parametric model to select a cutoff point for a pre-specified biomarker of the sensitive subpopulation. Both these methods have limitations. The first drawback is the strong assumption that the effect of the interaction between the biomarker and the treatment group on patient outcomes is a step-function with only one jump of the biomarker value. However, when the biomarker is continuous, it is most likely that the interaction continuously varies with the value of the biomarker. Another main drawback of Jiang's method is that the proposed model with an unknown cut point is not identifiable. One additional limitation of all above mentioned existing methods is that they are not based on a causal framework.
In this paper, for survival data in a randomized clinical trial with full compliance, we propose a new statistical framework for casual inference in assessing the effectiveness of predictive biomarkers and in selecting sensitive patients to one particular treatment. Our new statistical framework overcomes the limitations of the existing methods for evaluating predictive biomarkers in selecting optimal treatments for individual patients. Specifically, in this paper, we introduce a new concept, called the Biomarker Adjusted Treatment Effect (BATE) curve, which evaluated the treatment effect at each value of the predictive biomarker, rather than the subgroups defined by the the predictive biomarker (i.e., STEPP). This method is not a special case of STEPP method. The BATE curve is a graphical plot of the treatment effect as a function of the biomarker value and can be used to select an optimal treatment for an individual patient. Compared to the existing methods, the BATE curve is more robust, and can visually display the treatment effect on the patient's outcome as a function of the biomarker value. The BATE curve can have three practical uses. First, the BATE curve may be used to assess clinical utility of a predictive biomarker in a standard clinical trial. Second, the results from the BATE curve may be used to design a subsequent confirmation trial for validating the clinical utility of a predictive biomarker using biomarkerbased designs (see [7, 8] ). Third, the results from the BATE curve may be used to help physicians to choose a best treatment in their clinical practice.
This article is organized as follows. In Sections 2 and 3, we illustrate the mathematic definitions and applications of our proposed BATE curves to select cutoff points, distinguish sensitive patients from nonsensitive patients, and choose the optimal treatment for individual patients for the situation with multiple treatments. In Section 4, we propose an estimation method for BATE curves and derive
